HMPL-A580

HMPL-A580 is an orally bioavailable, potent, and selective small molecule inhibitor of the extracellular signal-regulated kinase 1 and 2 (ERK1/2), developed by Hutchmed. As the terminal kinases of the MAPK (mitogen-activated protein kinase) signaling pathway, ERK1 and ERK2 play a pivotal role in mediating cellular responses to growth factors and are frequently hyperactivated in various malignancies, often due to mutations in upstream components like RAS or BRAF. By inhibiting ERK1/2, HMPL-A580 aims to suppress tumor cell proliferation and survival, potentially overcoming resistance that develops against BRAF or MEK inhibitors. The agent is currently being investigated in a Phase I/IIa clinical trial for patients with advanced or metastatic solid tumors.